Engineered immune cells take aim at Hard-to-Treat scleroderma
NCT ID NCT06400303
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 22 times
Summary
This early-stage trial tests a treatment called KYV-101, which uses a patient's own modified immune cells to target and destroy certain B-cells thought to drive systemic sclerosis. The study involves 3 adults with active diffuse cutaneous systemic sclerosis. The main goals are to check safety and see if the therapy can improve disease symptoms, but it is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwell Health
Great Neck, New York, 11021, United States
-
Stanford University Medical Center
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.